Alnylam Pharmaceuticals· @Alnylam · X·· 8 天前AI 评分12
AI 导读
Zilebesiran 项目负责人 Simon Fox 分享了他从我们近期 #RNAi 圆桌会议中获得的三大要点。Zilebesiran 是一款在研 RNAi 疗法，正在高心血管风险且血压控制不佳的 #高血压 患者中开展评估。 了解更多：https://go-alnylam.com/4xCDYpW
正文
Zilebesiran Program Lead, Simon Fox, shares his top 3 takeaways from our recent #RNAi Roundtable. Zilebesiran is an investigational RNAi therapeutic being evaluated in patients with high cardiovascular risk and uncontrolled #hypertension.
Find out more here: https://go-alnylam.com/4xCDYpW
来源：Alnylam Pharmaceuticals · x.com